newsfilter
← Latest News
Business Wire·

Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

Zelicapavir Results in Shortened Symptom Duration in Pediatric Patients EDP-323 is Highly Effective in a Post-Exposure Prophylaxis Setting Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage